Atrogi touts data on mechanism of obesity candidate ATR-127

Sweden-based metabolic disorders company Atrogi, has announced a publication in the Journal of Molecular Metabolism of a research paper that validates the mechanism of action of the company’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications.

Unlike existing anti-obesity therapies that compromise lean muscle mass, ATR-127 induces significant weight loss while preserving crucial lean body mass. ATR-127 binds to both the beta-2 and beta-3 adrenergic receptors in a unique manner, allowing for precise modulation of downstream signaling cascades.

Unlike conventional approaches, ATR-127's innovative binding mechanism enables selective activation of specific signaling pathways. This unlocks the full therapeutic potential of beta-2 and beta-3 receptor agonism, maximizing beneficial effects on metabolism and body composition while mitigating the cardiovascular side effects commonly associated with indiscriminate receptor activation.